Abbott Laboratories (ABT)
NYSE:ABT
Want to see ABT full AI Analyst Report?
Top Page
Abbott Laboratories
(NYSE:ABT)
Select Model
Select Model
Rating:62Neutral
Price Target:
$97.00
▲(0.20% Upside)
Action:ReiteratedDate:04/30/26
ABT scores as a moderate-quality setup: solid fundamentals (margins, leverage, and ongoing free cash flow) and a generally positive growth outlook from management are key supports. The score is held back primarily by very weak technicals (stock well below major moving averages with depressed momentum), a high P/E valuation, and near-term cash-flow softness plus acquisition-related EPS dilution.
Positive Factors
Diversified healthcare portfolio
Abbott’s multi‑segment model (Devices, Diagnostics, Nutrition, Established Pharmaceuticals) spreads revenue across procedure‑driven, recurring consumables, consumer retail and international generics. This diversification lowers single‑market cyclicality, supports steadier revenue and cross‑sell over multi‑year horizons.
Negative Factors
Large debt issuance raises financing burden
A $20B senior‑notes financing materially increases contractual interest and principal obligations and reduces near‑term financial flexibility. Even with long maturities, higher fixed and floating interest exposure raises refinancing and rating risks and constrains capital allocation until leverage normalizes post‑integration.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified healthcare portfolio
Abbott’s multi‑segment model (Devices, Diagnostics, Nutrition, Established Pharmaceuticals) spreads revenue across procedure‑driven, recurring consumables, consumer retail and international generics. This diversification lowers single‑market cyclicality, supports steadier revenue and cross‑sell over multi‑year horizons.
Read all positive factors
Abbott Laboratories (ABT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$158.14B
Dividend Yield1.88%
Average Volume (3M)12.29M
Price to Earnings (P/E)41.6
Beta (1Y)0.24
Revenue Growth6.59%
EPS Growth-53.44%
CountryUS
Employees114,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.15
Shares Outstanding1,741,657,300
10 Day Avg. Volume11,129,795
30 Day Avg. Volume12,286,748
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue4.12
Enterprise Value/Gross Profit7.31
Enterprise Value/Ebitda17.22
Forecast
1Y Price Target
$121.00Price Target Upside24.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)5.48
Revenue Forecast (FY)$50.31B
Abbott Laboratories Business Overview & Revenue Model
Company Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Med...
How the Company Makes Money
Abbott makes money primarily by selling healthcare products to hospitals, clinical laboratories, distributors, pharmacies, retailers, government and private healthcare systems, and directly or indirectly to patients depending on the product catego...
Abbott Laboratories Key Performance Indicators (KPIs)
Any
Revenue by Geography
Shows how much revenue Abbott generates in different regions (U.S., Europe, Asia, emerging markets), revealing which markets drive sales and where the company is most exposed to economic slowdowns, currency swings, or regulatory changes. Useful for spotting geographic growth opportunities—such as rising demand for diagnostics or nutrition in developing markets—and risks if a large share of sales concentrates in one region.
Shows how much revenue Abbott generates in different regions (U.S., Europe, Asia, emerging markets), revealing which markets drive sales and where the company is most exposed to economic slowdowns, currency swings, or regulatory changes. Useful for spotting geographic growth opportunities—such as rising demand for diagnostics or nutrition in developing markets—and risks if a large share of sales concentrates in one region.
Data provided by:
The Fly
The FlyAbbott Laboratories Earnings Call Summary
Earnings Call Date:Apr 16, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 16, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive outlook driven by solid device performance, completion and strategic value of the Exact Sciences acquisition (adding ~$3 billion of sales), strong pipeline progress, and underlying comparable sales and EPS growth. However, near-term headwinds remain: a notably weak respiratory season that hit molecular testing, ongoing Nutrition volume recovery, China VBP lingering effects, and modest EPS dilution from the acquisition. Management emphasized confidence in execution and an expectation of growth acceleration in the second half of the year, balancing near-term caution with medium- to long-term upside.Positive Updates
Adjusted EPS and Guidance
Adjusted EPS of $1.15 in Q1 2026, up 6% year-over-year. Q2 adjusted EPS guidance of $1.25 to $1.31. Full-year adjusted EPS guidance midpoint revised to $5.48 (reflecting $0.20 dilution from Exact Sciences acquisition).
Negative Updates
Rapid & Molecular Diagnostics Decline
Rapid and Molecular Diagnostics sales declined 10% in Q1 on a comparable basis, driven by much weaker-than-expected respiratory virus testing demand due to an unusually weak respiratory season.
Read all updates
Q1-2026 Updates
Positive
Negative
Adjusted EPS and Guidance
Adjusted EPS of $1.15 in Q1 2026, up 6% year-over-year. Q2 adjusted EPS guidance of $1.25 to $1.31. Full-year adjusted EPS guidance midpoint revised to $5.48 (reflecting $0.20 dilution from Exact Sciences acquisition).
Read all positive updates
Company Guidance
Abbott updated its 2026 outlook to a comparable full‑year sales growth range of 6.5%–7.5% (now including Exact Sciences, which is expected to add ~$3.0B of incremental sales in 2026), reported Q1 comparable sales up 3.7% and adjusted EPS of $1.15 (up 6% y/y), and cut the full‑year EPS midpoint from $5.68 to $5.48 (reflecting $0.20 of acquisition‑related dilution); Q2 adjusted EPS is guided to $1.25–$1.31, FX helped Q1 sales by ~4% and is expected to favor full‑year reported sales by ~1% (Q2 FX roughly neutral), and Q1 operating metrics included adjusted gross margin 56.3% of sales, adjusted R&D 6.7% and adjusted SG&A 29.3%; management also called out business‑level Q1 trends (Diagnostics +2% comparable, Core Lab +3%, Rapid & Molecular −10%, Cancer Diagnostics +13%; Nutrition roughly in line with expectations; EPD +9%; Medical Devices +8.5%; CGM sales $2.0B, +7.5% with an expect turnaround to double‑digit growth in Q2).Abbott Laboratories Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.13B | 44.33B | 41.95B | 40.11B | 43.65B | 43.08B |
| Gross Profit | 25.45B | 24.61B | 21.32B | 20.04B | 22.32B | 23.21B |
| EBITDA | 10.80B | 11.55B | 10.83B | 10.61B | 11.89B | 12.16B |
| Net Income | 6.28B | 6.52B | 13.40B | 5.72B | 6.93B | 7.07B |
Balance Sheet | ||||||
| Total Assets | 110.43B | 86.71B | 81.41B | 73.21B | 74.44B | 75.20B |
| Cash, Cash Equivalents and Short-Term Investments | 7.29B | 8.94B | 7.97B | 7.28B | 10.17B | 10.25B |
| Total Debt | 34.05B | 15.07B | 15.28B | 15.87B | 17.95B | 19.25B |
| Total Liabilities | 57.73B | 33.94B | 33.51B | 34.39B | 37.53B | 39.17B |
| Stockholders Equity | 52.06B | 52.13B | 47.66B | 38.60B | 36.69B | 35.80B |
Cash Flow | ||||||
| Free Cash Flow | 7.38B | 7.39B | 6.35B | 5.06B | 7.80B | 8.65B |
| Operating Cash Flow | 9.46B | 9.57B | 8.56B | 7.26B | 9.58B | 10.53B |
| Investing Cash Flow | -22.28B | -2.42B | -2.34B | -3.13B | -1.74B | -2.01B |
| Financing Cash Flow | 13.06B | -6.31B | -5.40B | -7.09B | -7.64B | -5.49B |
Abbott Laboratories Technical Analysis
Negative
96.81
Price Trends
107.35
Negative
114.00
Negative
121.16
Negative
Market Momentum
-2.71
Positive
32.55
Neutral
32.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABT, the sentiment is Negative. The current price of 96.81 is below the 20-day moving average (MA) of 101.65, below the 50-day MA of 107.35, and below the 200-day MA of 121.16, indicating a bearish trend. The MACD of -2.71 indicates Positive momentum. The RSI at 32.55 is Neutral, neither overbought nor oversold. The STOCH value of 32.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABT.
Abbott Laboratories Risk Analysis
Abbott Laboratories disclosed 19 risk factors in its most recent earnings report. Abbott Laboratories reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Abbott Laboratories Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $22.98B | 30.97 | 32.44% | ― | 15.60% | 46.46% | |
75 Outperform | $48.14B | 30.46 | 10.61% | ― | 13.81% | 22.90% | |
67 Neutral | $103.96B | 28.29 | 9.54% | 2.76% | 6.88% | 9.06% | |
66 Neutral | $120.69B | 41.38 | 15.04% | 0.95% | 11.16% | 8.08% | |
63 Neutral | $85.62B | 17.42 | 15.40% | ― | 17.44% | 74.36% | |
62 Neutral | $158.14B | 41.63 | 11.43% | 1.88% | 6.59% | -53.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ABT
Abbott Laboratories
90.79
-37.47
-29.21%
BSX
Boston Scientific
57.61
-45.58
-44.17%
DXCM
Dexcom
59.55
-10.71
-15.24%
EW
Edwards Lifesciences
83.50
8.32
11.07%
MDT
Medtronic
80.97
-0.02
-0.02%
SYK
Stryker
315.13
-55.29
-14.93%
Abbott Laboratories Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Abbott Expands Board and Enhances Equity Incentive Programs
Positive
Apr 27, 2026
On April 24, 2026, Abbott Laboratories expanded its board to 13 members and appointed Kevin Conroy as a director, following a by-law amendment approved the same day. At its Annual Meeting on April 24, 2026, shareholders also re-elected the full sl...
Business Operations and StrategyLegal Proceedings
Abbott Reaches Preliminary Settlement in Derivative Governance Case
Neutral
Apr 17, 2026
Six shareholder derivative lawsuits tied to Abbott Laboratories’ U.S. infant formula business have been proceeding on a consolidated basis in federal court in Illinois, alleging that certain current and former directors and officers breached...
Business Operations and StrategyDelistings and Listing ChangesM&A Transactions
Abbott Finalizes Exact Sciences Acquisition, Expands Cancer Diagnostics
Positive
Mar 23, 2026
Abbott Laboratories, a global healthcare leader in diagnostics, medical devices, nutritionals and branded generics, has expanded its portfolio with a strong emphasis on cancer screening and precision oncology diagnostics. By integrating Exact Scie...
M&A TransactionsPrivate Placements and Financing
Abbott Laboratories Completes Major Senior Notes Offering
Positive
Mar 9, 2026
On March 9, 2026, Abbott Laboratories completed a $20 billion multi-tranche senior notes offering, issuing floating-rate and fixed-rate debt with maturities ranging from 2029 to 2066 through a syndicate led by major global underwriters. The notes ...
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Abbott Laboratories Prices $20 Billion Senior Notes Offering
Positive
Feb 26, 2026
On February 23, 2026, Abbott Laboratories entered into a pricing agreement with a syndicate of major investment banks to issue $20 billion in senior notes across multiple floating- and fixed-rate tranches maturing between 2029 and 2066. The sale o...
Business Operations and StrategyExecutive/Board Changes
Abbott Laboratories Streamlines Governance With Smaller Board
Neutral
Feb 20, 2026
On February 20, 2026, Abbott Laboratories’ board of directors approved an amendment to the company’s by-laws to reduce the size of the board from thirteen to twelve members, effective April 24, 2026. The change signals a streamlined go...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.